UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 4, 2010

 

 

Angiotech Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

British Columbia   000-30334   98-0226269

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

1618 Station Street

Vancouver, BC, Canada V6A 1B6

(Address of principal executive offices)

(604) 221-7676

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 8.01. OTHER EVENTS

On October 6, 2010, Angiotech Pharmaceuticals, Inc. (“Angiotech”) issued a press release relating to commencement of arbitration and litigation proceedings by QSR Holdings, Inc. against Angiotech and certain of its subsidiaries. The full text of Angiotech’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Any information disclosed in this Current Report on Form 8-K or the exhibits hereto shall not be construed as an admission that such information is material.

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

 

(d) Exhibits

 

Exhibit

Number

  

Description

99.1    Press Release, dated October 6, 2010.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

Angiotech Pharmaceuticals, Inc.

(Registrant)

Date: October 6, 2010     By:  

/s/    K. T HOMAS B AILEY        

     

K. Thomas Bailey

Chief Financial Officer

 

3

INDEX TO EXHIBITS

 

Exhibit

Number

  

Description

99.1    Press Release, dated October 6, 2010.

 

4

Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Angiotech Pharmaceuticals - Common Shares (MM) Charts.
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Angiotech Pharmaceuticals - Common Shares (MM) Charts.